Comment from American Academy of Neurology

Summary: The American Academy of Neurology supports the FDA's initiative to identify priority areas for drug repurposing, specifically highlighting chronic neurological conditions, neurodegenerative diseases, rare diseases, and pediatric disorders. They recommend leveraging electronic health record (EHR) databases, AI-driven network medicine, and master protocols to identify candidates, while also calling for streamlined regulatory pathways and federal grants to overcome financial and administrative barriers for non-profit and academic sponsors.